We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron Down 15.5% Year to Date: How to Play the Stock?
Read MoreHide Full Article
Shares of Regeneron Pharmaceuticals, Inc. (REGN - Free Report) have dropped 15.5% in the year so far compared with the industry’s decline of 6.3%.
The stock has underperformed the sector and the S&P 500 Index during this timeframe. While the stock’s performance was encouraging at the onset of 2024, challenges for lead drug Eylea have dampened investors’ sentiment of late.
Eylea Sales Decline Hampers REGN's Ophthalmology Unit
Eylea is an anti-vascular endothelial growth factor inhibitor approved for various ophthalmology indications.
However, Eylea’s sales have been under pressure due to competition from Roche’s (RHHBY - Free Report) Vabysmo. The uptake of Roche’s Vabysmo has been phenomenal. Roche has designed Vabysmo to block pathways involving Ang-2 and VEGF-A.
Biosimilar competition for Eylea is also worrisome.
To counter the decline in Eylea sales, Regeneron developed a higher dose of the drug. While the initial uptake of Eylea HD was encouraging as Eylea patients transitioned to the higher dose, it now seems Eylea HD will take some time to offset the rapid erosion in Eylea sales.
Regeneron has a collaboration agreement with Bayer (BAYRY - Free Report) for Eylea. Regeneron records the net product sales of Eylea and Eylea HD in the United States, and Bayer records its net product sales outside the country. Regeneron records its share of profits in connection with Eylea’s sales outside the United States.
Dupixent Boosts REGN’s Top Line
The company’s top line benefits from its share of profits/losses in connection with the global sales of Dupixent. Partner Sanofi (SNY - Free Report) records global net product sales of Dupixent.
Solid sales of Dupixent (approved for use in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis and eosinophilic esophagitis) have fueled the top line for both Sanofi and Regeneron.
SNY and REGN are working to expand the drug’s label further. The FDA recently approved Dupixent for chronic obstructive pulmonary disease (COPD). The approved indication is an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype.
Last month, the European Commission expanded Dupixent’s label to treat eosinophilic esophagitis in children as young as one year of age.
Strong demand trends and consistent label expansion should fuel Dupixent sales.
REGN’s Focus on Oncology
The company also has other arrows in its quiver. It is looking to strengthen its oncology franchise, which currently comprises Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous squamous cell carcinoma and advanced non-small cell lung cancer.
REGN’s oncology franchise got a boost with the European Commission's approval of odronextamab for treating adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma after two or more lines of systemic therapy. The drug has been approved under the brand name Ordspono.
However, the company’s efforts to get odronextamab approved in the United States suffered a setback. The regulatory body issued complete response letters (CRL) for its BLA for odronextamab in March 2024.
The FDA issued a CRL for the biologics license applicationBLA for linvoseltamab, a bispecific antibody targeting BCMA and CD3, in R/R multiple myeloma that has progressed after at least three prior therapies. The sole approvability issue identified is related to findings from a pre-approval inspection at a third-party fill/finish manufacturer. Resolution of this issue will be required for both FDA and EC regulatory approvals.
Earlier, a phase II study for fianlimab, an antibody to LAG-3, in combination with Libtayo for perioperative non-small cell lung cancer, and a phase II/III study for fianlimab, in combination with Libtayo for perioperative melanoma, were also initiated.
The successful development of these oncology drugs should be a great boost for REGN.
REGN: Valuation & Estimates
Going by the price/earnings ratio, REGN shares currently trade at 19.49 forward earnings, higher than its mean of 19.24 and the large-cap pharma industry’s 16.62.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2024 earnings per share has risen 55 cents to $45.14 over the past 60 days.
Image Source: Zacks Investment Research
Conclusion
Large biotech companies are considered safe havens for investors interested in this sector.
Regeneron is bearing the brunt of investors of late as Eylea’s sales witness a rapid decline. Earlier, the stock took a hit after an unfavorable ruling in its lawsuit against Amgen in the United States District Court for the Northern District of West Virginia related to a biosimilar of its Eylea.
The FDA also approved Amgen’s biosimilar of Eylea — Pavblu. This is the fifth biosimilar approved for Eylea.
While Regeneron has solid long-term growth prospects, the near-term pipeline setbacks and biosimilar challenges with Eylea are a concern for now. We would advise investors to wait and watch for the time being. For investors already owning the stock, staying invested at current levels will be prudent.
Image: Bigstock
Regeneron Down 15.5% Year to Date: How to Play the Stock?
Shares of Regeneron Pharmaceuticals, Inc. (REGN - Free Report) have dropped 15.5% in the year so far compared with the industry’s decline of 6.3%.
The stock has underperformed the sector and the S&P 500 Index during this timeframe. While the stock’s performance was encouraging at the onset of 2024, challenges for lead drug Eylea have dampened investors’ sentiment of late.
Regeneron Underperforms Industry, Sector & S&P 500
Image Source: Zacks Investment Research
Eylea Sales Decline Hampers REGN's Ophthalmology Unit
Eylea is an anti-vascular endothelial growth factor inhibitor approved for various ophthalmology indications.
However, Eylea’s sales have been under pressure due to competition from Roche’s (RHHBY - Free Report) Vabysmo. The uptake of Roche’s Vabysmo has been phenomenal. Roche has designed Vabysmo to block pathways involving Ang-2 and VEGF-A.
Biosimilar competition for Eylea is also worrisome.
To counter the decline in Eylea sales, Regeneron developed a higher dose of the drug. While the initial uptake of Eylea HD was encouraging as Eylea patients transitioned to the higher dose, it now seems Eylea HD will take some time to offset the rapid erosion in Eylea sales.
Regeneron has a collaboration agreement with Bayer (BAYRY - Free Report) for Eylea. Regeneron records the net product sales of Eylea and Eylea HD in the United States, and Bayer records its net product sales outside the country. Regeneron records its share of profits in connection with Eylea’s sales outside the United States.
Dupixent Boosts REGN’s Top Line
The company’s top line benefits from its share of profits/losses in connection with the global sales of Dupixent. Partner Sanofi (SNY - Free Report) records global net product sales of Dupixent.
Solid sales of Dupixent (approved for use in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis and eosinophilic esophagitis) have fueled the top line for both Sanofi and Regeneron.
SNY and REGN are working to expand the drug’s label further. The FDA recently approved Dupixent for chronic obstructive pulmonary disease (COPD). The approved indication is an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype.
Last month, the European Commission expanded Dupixent’s label to treat eosinophilic esophagitis in children as young as one year of age.
Strong demand trends and consistent label expansion should fuel Dupixent sales.
REGN’s Focus on Oncology
The company also has other arrows in its quiver. It is looking to strengthen its oncology franchise, which currently comprises Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous squamous cell carcinoma and advanced non-small cell lung cancer.
REGN’s oncology franchise got a boost with the European Commission's approval of odronextamab for treating adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma after two or more lines of systemic therapy. The drug has been approved under the brand name Ordspono.
However, the company’s efforts to get odronextamab approved in the United States suffered a setback. The regulatory body issued complete response letters (CRL) for its BLA for odronextamab in March 2024.
The FDA issued a CRL for the biologics license applicationBLA for linvoseltamab, a bispecific antibody targeting BCMA and CD3, in R/R multiple myeloma that has progressed after at least three prior therapies. The sole approvability issue identified is related to findings from a pre-approval inspection at a third-party fill/finish manufacturer. Resolution of this issue will be required for both FDA and EC regulatory approvals.
Earlier, a phase II study for fianlimab, an antibody to LAG-3, in combination with Libtayo for perioperative non-small cell lung cancer, and a phase II/III study for fianlimab, in combination with Libtayo for perioperative melanoma, were also initiated.
The successful development of these oncology drugs should be a great boost for REGN.
REGN: Valuation & Estimates
Going by the price/earnings ratio, REGN shares currently trade at 19.49 forward earnings, higher than its mean of 19.24 and the large-cap pharma industry’s 16.62.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2024 earnings per share has risen 55 cents to $45.14 over the past 60 days.
Image Source: Zacks Investment Research
Conclusion
Large biotech companies are considered safe havens for investors interested in this sector.
Regeneron is bearing the brunt of investors of late as Eylea’s sales witness a rapid decline. Earlier, the stock took a hit after an unfavorable ruling in its lawsuit against Amgen in the United States District Court for the Northern District of West Virginia related to a biosimilar of its Eylea.
The FDA also approved Amgen’s biosimilar of Eylea — Pavblu. This is the fifth biosimilar approved for Eylea.
While Regeneron has solid long-term growth prospects, the near-term pipeline setbacks and biosimilar challenges with Eylea are a concern for now. We would advise investors to wait and watch for the time being. For investors already owning the stock, staying invested at current levels will be prudent.
REGN currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.